S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
NASDAQ:AMYT

Amryt Pharma - AMYT Stock Forecast, Price & News

$14.55
-0.04 (-0.27%)
(As of 03/28/2023 05:12 PM ET)
Add
Compare
Today's Range
$14.55
$14.60
50-Day Range
$14.55
$14.70
52-Week Range
$6.41
$14.77
Volume
1.68 million shs
Average Volume
741,066 shs
Market Capitalization
$930.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.42

Amryt Pharma MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
6.0% Upside
$15.42 Price Target
Short Interest
Healthy
0.19% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.43mentions of Amryt Pharma in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.13) to $0.02 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.54 out of 5 stars

Medical Sector

923rd out of 1,002 stocks

Pharmaceutical Preparations Industry

446th out of 488 stocks


AMYT stock logo

About Amryt Pharma (NASDAQ:AMYT) Stock

Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.

Receive AMYT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amryt Pharma and its competitors with MarketBeat's FREE daily newsletter.

AMYT Stock News Headlines

Amryt Pharma Stock (NASDAQ:AMYT), Dividends
JP Morgan analyst: Oil to hit $380 per barrel
JP Morgan analysts have pegged the future price of oil at $380 per barrel. That would send oil companies skyrocketing. But there is one investment set to outperform all the rest.
Maxim Group Reaffirms Their Buy Rating on Amryt Pharma (AMYT)
SVB Securities Keeps Their Buy Rating on Amryt Pharma (AMYT)
Biden’s Big Lie…
Biden is about to steal the 2024 election... Not through voter suppression, collision with Big Tech, or anything else you might be thinking of. pixel
Amryt Reports Q3 2022 Financial and Operational Results
Amryt Supports Global EB Awareness Week 2022
Amryt to Report Q3 2022 Results on November 3, 2022
Amryt Supports FH Awareness Day – September 24, 2022
Amryt Reports Record Q2 2022 Results
Amryt to Report Q2 2022 Results on August 4, 2022
See More Headlines
Receive AMYT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amryt Pharma and its competitors with MarketBeat's FREE daily newsletter.

AMYT Company Calendar

Last Earnings
11/05/2020
Today
3/28/2023
Next Earnings (Estimated)
3/29/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AMYT
Fax
N/A
Employees
2,020
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.42
High Stock Price Forecast
$17.00
Low Stock Price Forecast
$14.50
Forecasted Upside/Downside
+6.0%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
5 Analysts

Profitability

Net Income
$1 million
Pretax Margin
-0.56%

Debt

Sales & Book Value

Annual Sales
$222.54 million
Cash Flow
$0.98 per share
Book Value
$5.58 per share

Miscellaneous

Free Float
N/A
Market Cap
$930.62 million
Optionable
Not Optionable
Beta
0.86

Key Executives

  • Dr. Joseph A. Wiley (Age 51)
    CEO & Director
    Comp: $1.65M
  • Mr. Rory P. Nealon (Age 54)
    CFO, COO & Company Sec.
    Comp: $890k
  • Ms. Elizabeth Varki Jobes J.D. (Age 55)
    Chief Compliance Officer
  • Mr. John McEvoy
    Gen. Counsel
  • Mr. Stephen Joyce
    Head of Marketing & Head of APAC
  • Ms. Julie Eastwood
    Head of HR
  • Dr. Helen Phillips
    Head of Medical Affairs
  • Ms. Sheila M. Frame (Age 60)
    Pres of Americas
  • Dr. Tracy Cunningham
    Chief Medical Officer
  • Mr. Jordi Casals
    Pres of EMEA Region













AMYT Stock - Frequently Asked Questions

Should I buy or sell Amryt Pharma stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amryt Pharma in the last twelve months. There are currently 5 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" AMYT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMYT, but not buy additional shares or sell existing shares.
View AMYT analyst ratings
or view top-rated stocks.

What is Amryt Pharma's stock price forecast for 2023?

5 analysts have issued 1-year target prices for Amryt Pharma's shares. Their AMYT share price forecasts range from $14.50 to $17.00. On average, they expect the company's share price to reach $15.42 in the next twelve months. This suggests a possible upside of 6.0% from the stock's current price.
View analysts price targets for AMYT
or view top-rated stocks among Wall Street analysts.

How have AMYT shares performed in 2023?

Amryt Pharma's stock was trading at $7.30 on January 1st, 2023. Since then, AMYT shares have increased by 99.3% and is now trading at $14.55.
View the best growth stocks for 2023 here
.

Are investors shorting Amryt Pharma?

Amryt Pharma saw a increase in short interest in March. As of March 15th, there was short interest totaling 121,200 shares, an increase of 56.2% from the February 28th total of 77,600 shares. Based on an average trading volume of 646,300 shares, the short-interest ratio is presently 0.2 days.
View Amryt Pharma's Short Interest
.

When is Amryt Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 29th 2023.
View our AMYT earnings forecast
.

How were Amryt Pharma's earnings last quarter?

Amryt Pharma plc (NASDAQ:AMYT) announced its quarterly earnings data on Thursday, November, 5th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.66. The firm earned $49.33 million during the quarter. Amryt Pharma had a negative net margin of 8.19% and a positive trailing twelve-month return on equity of 1.70%.

What other stocks do shareholders of Amryt Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amryt Pharma investors own include Immunic (IMUX), Ampio Pharmaceuticals (AMPE), Chimerix (CMRX), Livongo Health (LVGO), Otonomy (OTIC), Akero Therapeutics (AKRO), Albireo Pharma (ALBO), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD) and Applied DNA Sciences (APDN).

What is Amryt Pharma's stock symbol?

Amryt Pharma trades on the NASDAQ under the ticker symbol "AMYT."

Who are Amryt Pharma's major shareholders?

Amryt Pharma's stock is owned by many different institutional and retail investors. Top institutional shareholders include Stonepine Capital Management LLC (9.90%), Handelsbanken Fonder AB (2.21%), Armistice Capital LLC (1.53%), Wells Fargo & Company MN (0.46%), Silverarc Capital Management LLC (0.30%) and Millennium Management LLC (0.22%).

How do I buy shares of Amryt Pharma?

Shares of AMYT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amryt Pharma's stock price today?

One share of AMYT stock can currently be purchased for approximately $14.55.

How much money does Amryt Pharma make?

Amryt Pharma (NASDAQ:AMYT) has a market capitalization of $930.62 million and generates $222.54 million in revenue each year. The company earns $1 million in net income (profit) each year or ($0.06) on an earnings per share basis.

How many employees does Amryt Pharma have?

The company employs 2,020 workers across the globe.

How can I contact Amryt Pharma?

Amryt Pharma's mailing address is DEPT 920A 196 HIGH ROAD WOOD GREEN, LONDON X0, D02 CR98. The official website for the company is www.amrytpharma.com. The company can be reached via phone at 353-1518-0200 or via email at ir@amrytpharma.com.

This page (NASDAQ:AMYT) was last updated on 3/28/2023 by MarketBeat.com Staff